跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/KCT0004390
KCT0004390招募中未知

eoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ) adenocarcinoma

Asan Medical Center0 个研究点目标入组 68 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
招募中
入组人数
68
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 0No Limit（—）
性别
All

入选标准

  • •Newly diagnosed pathologically proven potentially resectable gastric or GEJ adenocarcinoma
  • •Clinical stages of T3–4N0 or T2–4N+ according to the American Joint Committee on Cancer (AJCC) 8th edition by computed tomography (CT)
  • •Microsatellite-instability (MSI) status determined by immunohistochemical (IHC) staining
  • •No peritoneal seeding identified by laparoscopy if suspected by CT
  • •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • •Age > 18 years at time of study entry
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • •Life expectancy of > 12 months
  • •Body weight > 30kg
  • •No existing neuropathy
  • •Adequate normal organ and marrow function as defined below:
  • •-Haemoglobin =9.0 g/dL
  • •-Absolute neutrophil count (ANC) 1.5 (or 1.0) x (> 1500 per mm3)
  • •-Platelet count =100 (or 75) x 109/L (>75,000 per mm3)
  • •-Serum bilirubin =1.5 x institutional upper limit of normal (ULN)
  • •-AST (SGOT)/ALT (SGPT) =2.5 x institutional ULN
  • •-Measured creatinine clearance (CL) > 40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
  • •Creatinine CL (mL/min)=Weight (kg) x (140 – Age)
  • •72 x serum creatinine (mg/dL)
  • •Creatinine CL (mL/min)=Weight (kg) x (140 – Age) x 0.85
  • •72 x serum creatinine (mg/dL)
  • •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
  • •-Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)
  • •-Women =50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
  • •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

排除标准

  • •Participation in another clinical study with an investigational product during the last 2 weeks
  • •Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  • •Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
  • •Major surgical procedure within 28 days prior to the first dose of durvalumab
  • •Distant metastasis including M1 lymph node
  • •Unable to take medication orally
  • •Gastric outlet obstruction and/or severe gastrointestinal bleeding
  • •Impaired bowel absorption, including any of the following:
  • •-Bowel obstruction
  • •-Chronic inflammatory bowel disease
  • •-History of extended bowel resection
  • •-Gastric dumping syndrome
  • •History of allogenic organ transplantation
  • •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
  • •a.Patients with vitiligo or alopecia
  • •b.Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
  • •c.Any chronic skin condition that does not require systemic therapy
  • •d.Patients without active disease in the last 5 years may be included but only after consultation with the study physician
  • •e.Patients with celiac disease controlled by diet alone
  • •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
  • •History of another primary malignancy except for
  • •a.Malignancy treated with curative intent and with no known active disease = 5 years before the first dose of durvalumab and of low potential risk for recurrence
  • •b.Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • •c.Adequately treated carcinoma in situ without evidence of disease
  • •Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) =470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)
  • •History of active primary immunodeficiency
  • •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • •Current or pri

研究者

相似试验

已完成
2 期
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction AdenocarcinomaResectable Gastric or Gastroesophageal Junction Adenocarcinoma
NCT04221555Asan Medical Center68
进行中（未招募）
1 期
Treatment to modulate the activity of the immune system in combination with chemotherapy treatment in patients with operable urothelial cancer
EUCTR2017-003565-10-DESwiss Group for Clinical Cancer Research61
进行中（未招募）
1 期
eoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer - EXPRESSIOEligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2008-006381-29-DEniversitätsmedizin Mainz200
招募中
2 期
Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
2024-511511-25-00UZ Leuven21
进行中（未招募）
2 期
Docetaxel plus Ramucirumab immediately after treatment with ICInon-small cell lung cancer, adenocarcinoma, squamous cell carcinomanon-small cell lung cancer
JPRN-jRCT1051190091Akamatsu Hiroaki35